 HEIDELBERG, Germany, May 24, 2022 GLOBE NEWSWIRE -- Affimed N.V. Nasdaq: AFMD Affimed, or the Company, a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2022 results and corporate update on Wednesday, June 1, 2022. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time. 